Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001958657 | SCV002235156 | pathogenic | Fabry disease | 2021-05-19 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine with proline at codon 301 of the GLA protein (p.Arg301Pro). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is not present in population databases (ExAC no frequency). For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Arg301 amino acid residue in GLA. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 12175777, 23935525, 27657681, Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Experimental studies have shown that this variant affects GLA protein function (PMID: 22004918, 23935525). This variant has been observed in individual(s) with Fabry disease (PMID: 11322659, 27834756, 15702404, Invitae). |